Antonio Rossi

Antonio Rossi

Auto-generated profile, based on publicly available information

Antonio Rossi

University of Toronto

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 May 2026 in Journal of the American Heart Association
Verified
Journal Article
Closed access
SBSonghee Back
Songhee Back
SYShuting Yang
Shuting Yang
ARAntonio Rossi
Antonio Rossi
SASabrina Ayoub-Charette
Sabrina Ayoub-Charette
SGShannan M Grant
Shannan M Grant
Laura ChiavaroliLaura Chiavaroli
Laura Chiavaroli
Background: Although dietary pulses are recognized by major clinical practice guidelines to reduce cholesterol and coronary heart disease risk, intake is low. There are no health claims for any pulse for cholesterol reduction, which could support uptake. We therefore conducted a systematic review and dose–response meta‐analysis of randomized trials of the effect of different types of whole dietary pulses on lipid targets. Methods: MEDLINE, Embase, and the Cochrane Library were searched through March 2025 for trials ≥3 weeks. The primary outcome was low‐density lipoprotein‐cholesterol. Secondary outcomes were other lipid targets. Independent reviewers extracted data and assessed risk of bias. Certainty of evidence was assessed using Grading of Recommendations Assessment, Development, and Evaluation. Results: Thirty‐eight trials (52 trial comparisons, n=2095) with a median of 6 weeks and dose of 130 g/d (0.5–0.67 cup/d) showed that whole dietary pulses decreased low‐density lipoprotein‐cholesterol (mean difference, −0.14 mmol/L [95% CI, −0.19 to −0.08]), non‐high‐density lipoprotein‐cholesterol (−0.22 mmol/L [95% CI, −0.30 to −0.14]), apoB (apolipoprotein B) (−0.08 g/L [95% CI, −0.13 to −0.03]) and high‐density lipoprotein‐cholesterol (−0.03 mmol/L [95% CI, −0.05 to −0.01]) with no effects on other lipids. Analyses by pulse type showed similar results. A linear inverse relationship was shown for beans up to 1 cup/d for low‐density lipoprotein‐cholesterol (coefficient, −0.25 mmol/L/0.5 cup [95% CI, −0.48 to −0.02]) and non‐high‐density lipoprotein‐cholesterol (−0.45 mmol/L/0.5 cup [95% CI, −0.71 to −0.18]). Grading of Recommendations Assessment, Development, and Evaluation was moderate‐to‐high for all outcomes, except apoB (very low). Conclusions: Whole dietary pulses likely result in small important‐to‐moderate reductions in lipid targets and trivial reductions in high‐density lipoprotein‐cholesterol. Similar effects were observed across pulse types with an inverse dose–response gradient for beans up to 1 cup/d. Future studies on chickpeas, dried peas, and lentils are warranted. Registration: URL: https://www.crd.york.ac.uk/PROSPERO/view/CRD42023432826 ; Unique identifier: CRD42023432826.

3 November 2026 in Journal of the American Heart Association
Verified
Journal Article
Closed access
ZHZeinab Houshialsadat
Zeinab Houshialsadat
GVGabrielle Viscardi
Gabrielle Viscardi
ARAntonio G. Rossi
Antonio G. Rossi
SASabrina Ayoub-Charette
Sabrina Ayoub-Charette
DCDayana El Chaar
Dayana El Chaar
Laura ChiavaroliLaura Chiavaroli
Laura Chiavaroli
Background: Cardiovascular disease remains the leading cause of death and hospitalization globally. Clinical practice guidelines recommend various plant‐based dietary patterns that target specific cardiometabolic risk factors, including the Dietary Approach to Stop Hypertension (DASH) diet for blood pressure and the Portfolio diet for low‐density lipoprotein cholesterol. Combining key elements of these patterns may enhance cardiovascular disease risk reduction. However, many soy‐based products, a key Portfolio component, are classified as ultra‐processed foods (UPFs). This trial will answer 2 questions: (1) Does a DASH‐enhanced Portfolio diet result in clinically meaningful reductions in blood pressure compared with standard of care and (2) Is a high‐UPF noninferior to a low‐UPF soy protein‐containing DASH‐enhanced Portfolio diet for blood pressure reduction? Methods: The SWITCH (Substitution of High With Low Ultra‐Processed Soy Protein Foods in a Guideline‐Based Diet Intervention for Cardiometabolic Health) trial is a parallel, randomized, 3‐arm, open‐label, superiority–noninferiority trial. Three hundred adults with hypertension and obesity, including 50% with type 2 diabetes, will be randomized to a high‐UPF or low‐UPF soy protein‐containing DASH‐enhanced Portfolio diet or standard of care for 12 weeks. The primary outcome is systolic blood pressure. Key secondary outcomes are non–high‐density lipoprotein cholesterol and body weight. Other outcomes include cardiometabolic risk factors. Conclusions: Findings will provide high‐quality evidence on the use of a DASH‐enhanced Portfolio diet and the role of nutrient‐dense soy foods classified as UPFs within the combination of the 2 guideline‐based dietary patterns to support dietary strategies for cardiometabolic risk reduction. REGISTRATION: URL: https://clinicaltrials.gov/ ; Unique identifier: NCT06907862.